NCT03872180View on ClinicalTrials.gov

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

June 6, 2022

Study Completion Date

April 30, 2026

Conditions
CCND1 PositiveMantle Cell Lymphomat(11;14) Positive
Interventions
DRUG

Bendamustine

Given IV

BIOLOGICAL

Obinutuzumab

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (3)

30097

Emory Johns Creek Hospital, Johns Creek

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER